Skip to main content
Clinical Trials/KCT0002440
KCT0002440
Not yet recruiting
未知

Safety, effectiveness, and cost-effectiveness of an herbal medicine, Gongjin-dan, in subjects with chronic dizziness: a prospective, multicenter, randomized, double-blinded, placebo-controlled, parallel-group, clinical trial

Kyung Hee University0 sites78 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Kyung Hee University
Enrollment
78
Status
Not yet recruiting
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional Study
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\) Age between 20 and 79 years, of either sex
  • 2\) Dizziness originating from Ménière disease, psychogenic cause, or unknown cause
  • 3\) Recurring symptom of dizziness for more than 1 month
  • 4\) Dizziness Handicap Inventory (DHI) score \= 24 at baseline
  • 5\) Liver\-deficiency pattern/syndrome identified by Traditional Korean Medicine doctors
  • 6\) Willingness to provide written informed consent

Exclusion Criteria

  • 1\) Dizziness attributable to vestibular disorders (e.g., benign paroxysmal positional vertigo, peripheral vestibulopathy, labyrinthitis, vestibular neuronitis, and others)
  • 2\) Dizziness attributable to central nervous system (CNS) disorders (e.g., cerebellar ataxia, stroke, demyelination, vertebrobasilar insufficiency, seizure, increased intracranial pressure, Parkinson's disease, migraines, and others)
  • 3\) Cervicogenic dizziness
  • 4\) Dizziness attributable to cardiovascular disorders (e.g., arrhythmia, heart valvular disease, anemia, orthostatic hypotension, coronary artery disease, and others)
  • 5\) Any active or uncontrolled disease that might cause dizziness (e.g., uncontrolled diabetes mellitus, hypertension, respiratory or endocrinological disorders, and others)
  • 6\) Dizziness attributable to medication side effects
  • 7\) Severe chronic or terminal diseases (malignant cancer, tuberculosis, and others)
  • 8\) Intake of other antivertiginous drugs that cannot be discontinued
  • 9\) Following physiotherapy, manual therapy (e.g., vestibular rehabilitation), and/or cognitive behavioral therapy for the treatment of dizziness
  • 10\) Aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood urea nitrogen (BUN), or creatinine \> 3 × upper limit of normal range at baseline

Outcomes

Primary Outcomes

Not specified

Similar Trials